Literature DB >> 21540878

Transcription by RNA polymerase III: more complex than we thought.

Robert J White1.   

Abstract

RNA polymerase (Pol) III is highly specialized for the production of short non-coding RNAs. Once considered to be under relatively simple controls, recent studies using chromatin immunoprecipitation followed by sequencing (ChIP-seq) have revealed unexpected levels of complexity for Pol III regulation, including substantial cell-type selectivity and intriguing overlap with Pol II transcription. Here I describe these novel insights and consider their implications and the questions that remain.

Mesh:

Substances:

Year:  2011        PMID: 21540878     DOI: 10.1038/nrg3001

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  40 in total

Review 1.  Recruitment of RNA polymerase III to its target promoters.

Authors:  Laura Schramm; Nouria Hernandez
Journal:  Genes Dev       Date:  2002-10-15       Impact factor: 11.361

Review 2.  Regulation of RNA polymerase III transcription by Maf1 protein.

Authors:  Małgorzata Cieśla; Magdalena Boguta
Journal:  Acta Biochim Pol       Date:  2008-06-17       Impact factor: 2.149

3.  RNA polymerase III and RNA polymerase II promoter complexes are heterochromatin barriers in Saccharomyces cerevisiae.

Authors:  D Donze; R T Kamakaka
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

4.  Two steps in Maf1-dependent repression of transcription by RNA polymerase III.

Authors:  Neelam Desai; Jaehoon Lee; Rajendra Upadhya; Yaya Chu; Robyn D Moir; Ian M Willis
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

5.  Alpha-amanitin: a specific inhibitor of one of two DNA-pendent RNA polymerase activities from calf thymus.

Authors:  C Kedinger; M Gniazdowski; J L Mandel; F Gissinger; P Chambon
Journal:  Biochem Biophys Res Commun       Date:  1970-01-06       Impact factor: 3.575

6.  Multiple forms of DNA-dependent RNA polymerase in eukaryotic organisms.

Authors:  R G Roeder; W J Rutter
Journal:  Nature       Date:  1969-10-18       Impact factor: 49.962

7.  Epstein-Barr virus-encoded EBNA1 enhances RNA polymerase III-dependent EBER expression through induction of EBER-associated cellular transcription factors.

Authors:  Thomas J Owen; John D O'Neil; Christopher W Dawson; Chunfang Hu; Xiaoyi Chen; Yunhong Yao; Victoria H J Wood; Louise E Mitchell; Robert J White; Lawrence S Young; John R Arrand
Journal:  Mol Cancer       Date:  2010-09-15       Impact factor: 27.401

8.  TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription.

Authors:  Niall S Kenneth; Ben A Ramsbottom; Natividad Gomez-Roman; Lynne Marshall; Philip A Cole; Robert J White
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-11       Impact factor: 11.205

9.  Pol II and its associated epigenetic marks are present at Pol III-transcribed noncoding RNA genes.

Authors:  Artem Barski; Iouri Chepelev; Dritan Liko; Suresh Cuddapah; Alastair B Fleming; Joanna Birch; Kairong Cui; Robert J White; Keji Zhao
Journal:  Nat Struct Mol Biol       Date:  2010-04-25       Impact factor: 15.369

10.  Human RNA polymerase III transcriptomes and relationships to Pol II promoter chromatin and enhancer-binding factors.

Authors:  Andrew J Oler; Ravi K Alla; Douglas N Roberts; Alexander Wong; Peter C Hollenhorst; Katherine J Chandler; Patrick A Cassiday; Cassie A Nelson; Curt H Hagedorn; Barbara J Graves; Bradley R Cairns
Journal:  Nat Struct Mol Biol       Date:  2010-04-25       Impact factor: 15.369

View more
  98 in total

Review 1.  Something silent this way forms: the functional organization of the repressive nuclear compartment.

Authors:  Joan C Ritland Politz; David Scalzo; Mark Groudine
Journal:  Annu Rev Cell Dev Biol       Date:  2013-07-05       Impact factor: 13.827

2.  Genomic and proteomic analyses of Prdm5 reveal interactions with insulator binding proteins in embryonic stem cells.

Authors:  Giorgio Giacomo Galli; Matteo Carrara; Chiara Francavilla; Kristian Honnens de Lichtenberg; Jesper Velgaard Olsen; Raffaele Adolfo Calogero; Anders Henrik Lund
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

3.  Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system.

Authors:  Kabin Xie; Bastian Minkenberg; Yinong Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

4.  Translation regulation in skin cancer from a tRNA point of view.

Authors:  Katerina Grafanaki; Dimitrios Anastasakis; George Kyriakopoulos; Ilias Skeparnias; Sophia Georgiou; Constantinos Stathopoulos
Journal:  Epigenomics       Date:  2018-12-19       Impact factor: 4.778

5.  Differential phosphorylation of a regulatory subunit of protein kinase CK2 by target of rapamycin complex 1 signaling and the Cdc-like kinase Kns1.

Authors:  Manuel E Sanchez-Casalongue; Jaehoon Lee; Aviva Diamond; Scott Shuldiner; Robyn D Moir; Ian M Willis
Journal:  J Biol Chem       Date:  2015-01-28       Impact factor: 5.157

Review 6.  Regulation of mammalian cell differentiation by long non-coding RNAs.

Authors:  Wenqian Hu; Juan R Alvarez-Dominguez; Harvey F Lodish
Journal:  EMBO Rep       Date:  2012-10-16       Impact factor: 8.807

Review 7.  Transcription termination by the eukaryotic RNA polymerase III.

Authors:  Aneeshkumar G Arimbasseri; Keshab Rijal; Richard J Maraia
Journal:  Biochim Biophys Acta       Date:  2012-10-23

8.  Insertion of an Alu element in a lncRNA leads to primate-specific modulation of alternative splicing.

Authors:  Shanshan Hu; Xiaolin Wang; Ge Shan
Journal:  Nat Struct Mol Biol       Date:  2016-10-03       Impact factor: 15.369

9.  Epigenomic model of cardiac enhancers with application to genome wide association studies.

Authors:  Avinash Das Sahu; Radhouane Aniba; Yen-Pei Christy Chang; Sridhar Hannenhalli
Journal:  Pac Symp Biocomput       Date:  2013

Review 10.  Dysregulation of the basal RNA polymerase transcription apparatus in cancer.

Authors:  Megan J Bywater; Richard B Pearson; Grant A McArthur; Ross D Hannan
Journal:  Nat Rev Cancer       Date:  2013-05       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.